Trigeminal Neuralgia Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Summary
GlobalData, the industry analysis specialist, has released its new report, “Trigeminal Neuralgia Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Trigeminal Neuralgia Therapeutics market. The report identifies the key trends shaping and driving the global Trigeminal Neuralgia Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Trigeminal Neuralgia Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
Scope
The report provides information on the key drivers and challenges of the Trigeminal Neuralgia Therapeutics market. Its Scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Trigeminal Neuralgia Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Trigeminal Neuralgia Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Trigeminal Neuralgia Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Trigeminal Neuralgia Therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Trigeminal Neuralgia Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Trigeminal Neuralgia Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Trigeminal Neuralgia Therapeutics market landscape? – Identify, understand and capitalize.
Therapy Industry in the United Kingdom
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 5
2 Trigeminal Neuralgia Therapeutics - Introduction 7
2.1 Disease Overview 7
2.1.1 Pain Distribution in the Various Nerve Branches in Trigeminal Neuralgia 7
2.1.2 Anatomy of Trigeminal Nerve Branches 8
2.1.3 Definition of Trigeminal Neuralgia 9
2.1.4 Types of Trigeminal Neuralgia 10
2.1.5 Progression of Trigeminal Neuralgia 11
2.2 Epidemiology 12
2.2.1 Annual Incidence 12
2.2.2 Age 13
2.2.3 Gender 13
2.2.4 Disease Burden 13
2.2.5 Quality of Life Parameters 14
2.3 Etiology and Pathophysiology 14
2.3.1 Neurovasculer Compression 14
2.3.2 Chronic Focal Demyelination of Nerve 16
2.3.3 Prognosis 17
2.4 Signs and Symptoms 17
2.4.1 Clinical Signs of Trigeminal Neuralgia 17
2.4.2 Symptoms 18
2.5 Diagnosis 19
2.5.1 History 20
2.5.2 Physical Examination 20
2.5.3 Ancillary Testing 20
2.5.4 Differential Diagnosis 20
2.6 Treatment and Management Pattern 21
2.6.1 Pharmacological Approach 23
2.6.2 Surgical Approach 25
2.7 Referral Pathway 31
2.8 GlobalData Pipeline Report Guidance 32
3 Trigeminal Neuralgia Therapeutics - Market Characterization 33
3.1 Overview 33
3.2 Trigeminal Neuralgia Therapeutics Market Size (2006-2011) - Global 33
3.3 Trigeminal Neuralgia Therapeutics Market Forecast (2011-2019) - Global 34
3.4 Trigeminal Neuralgia Therapeutics Market Size (2006-2011) - The US 35
3.5 Trigeminal Neuralgia Therapeutics Market Forecast (2011-2019) - The US 36
3.6 Trigeminal Neuralgia Therapeutics Market Size (2006-2011) - France 37
3.7 Trigeminal Neuralgia Therapeutics Market Forecast (2011-2019) - France 38
3.8 Trigeminal Neuralgia Therapeutics Market Size (2006-2011) - Germany 39
3.9 Trigeminal Neuralgia Therapeutics Market Forecast (2011-2019) - Germany 40
3.10 Trigeminal Neuralgia Therapeutics Market Size (2006-2011) - Italy 41
3.11 Trigeminal Neuralgia Therapeutics Market Forecast (2011-2019) - Italy 42
3.12 Trigeminal Neuralgia Therapeutics Market Size (2006-2011) - Spain 43
3.13 Trigeminal Neuralgia Therapeutics Market Forecast (2011-2019) - Spain 44
3.14 Trigeminal Neuralgia Therapeutics Market Size (2006-2011) - The UK 45
3.15 Trigeminal Neuralgia Therapeutics Market Forecast (2011-2019) - The UK 46
3.16 Trigeminal Neuralgia Therapeutics Market Size (2006-2011) - Japan 47
3.17 Trigeminal Neuralgia Therapeutics Market Forecast (2011-2019) - Japan 48
3.18 Drivers and Barriers for the Trigeminal Neuralgia Therapeutics Market 49
3.18.1 Drivers for the Trigeminal Neuralgia Therapeutics Market 49
3.18.2 Barriers for the Trigeminal Neuralgia Therapeutics Market 50
3.19 Opportunity and Unmet Need Analysis 50
3.20 Key Takeaway 52
4 Trigeminal Neuralgia Therapeutics - Competitive Assessment 53
4.1 Overview 53
4.1.1 Strategic Competitor Assessment 53
4.2 Product Profiles for the Major Marketed Products in the Trigeminal Neuralgia Therapeutics Market 54
4.2.1 Carbamazepine 54
4.2.2 Other Common Drugs Used as Off-label for Trigeminal Neuralgia 56
4.3 Key Takeaway 57
5 Trigeminal Neuralgia Therapeutics - Pipeline Assessment 58
5.1 Overview 58
6 Trigeminal Neuralgia Therapeutics - Clinical Trials Mapping 59
6.1 Clinical Trials by Region/Country (US, EU5 and Japan) 59
6.2 Clinical Trials by Phase 60
6.3 Clinical Trials by Trial Status 61
6.4 Prominent Sponsors 62
6.5 Top Companies Participating in Trigeminal Neuralgia Therapeutics Clinical Trials 63
7 Strategic Assessment 64
7.1 Key Events Impacting the Future Market 64
7.2 Trigeminal Neuralgia Therapeutics: Implications for Future Market Competition 65
8 Trigeminal Neuralgia Therapeutics - Future Players 66
8.1 Company Profiles 66
8.1.1 Novartis 66
9 Trigeminal Neuralgia Therapeutics - Appendix 68
9.1 Market Definitions 68
9.2 Acronyms 68
9.3 Bibliography 69
9.4 Research Methodology 70
9.4.1 Coverage 70
9.4.2 Secondary Research 70
9.4.3 Primary Research 71
9.4.4 Modeling and Forecasting 71
9.4.5 Expert Panel Validation 73
9.5 Contact Us 74
9.6 Disclaimer 74
List of Tables
Table 1: Branches of Trigeminal Nerve- Areas and Function of Each Branch 7
Table 2: Prevalent Pool of Trigeminal Neuralgia in the Seven Major Markets 12
Table 3: Trigeminal Neuralgia Therapeutics Market, Global, Revenue ($m), 2006-2011 34
Table 4: Trigeminal Neuralgia Therapeutics Market, Global, Forecast ($m), 2011-2019 34
Table 5: Trigeminal Neuralgia Therapeutics Market, The US, Revenue ($m), 2006-2011 35
Table 6: Trigeminal Neuralgia Therapeutics Market, The US, Forecast ($m), 2011-2019 36
Table 7: Trigeminal Neuralgia Therapeutics Market, France, Revenue ($m), 2006-2011 37
Table 8: Trigeminal Neuralgia Therapeutics Market, France, Forecast ($m), 2011-2019 38
Table 9: Trigeminal Neuralgia Therapeutics Market, Germany, Revenue ($m), 2006-2011 39
Table 10: Trigeminal Neuralgia Therapeutics Market, Germany, Forecast ($m), 2011-2019 40
Table 11: Trigeminal Neuralgia Therapeutics Market, Italy, Revenue ($m), 2006-2011 41
Table 12: Trigeminal Neuralgia Therapeutics Market, Italy, Forecast ($m), 2011-2019 42
Table 13: Trigeminal Neuralgia Therapeutics Market, Spain, Revenue ($m), 2006-2011 43
Table 14: Trigeminal Neuralgia Therapeutics Market, Spain, Forecast ($m), 2011-2019 44
Table 15: Trigeminal Neuralgia Therapeutics Market, The UK, Revenue ($m), 2006-2011 45
Table 16: Trigeminal Neuralgia Therapeutics Market, The UK, Forecast ($m), 2011-2019 46
Table 17: Trigeminal Neuralgia Therapeutics Market, Japan, Revenue ($m), 2006-2011 47
Table 18: Trigeminal Neuralgia Therapeutics Market, Japan, Forecast ($m), 2011-2019 48
Table 19: Trigeminal Neuralgia Therapeutics, Clinical Trials by Country, 2012 59
Table 20: Trigeminal Neuralgia Therapeutics, Clinical Trials by Phase, 2012 60
Table 21: Trigeminal Neuralgia Therapeutics, Clinical Trials by Status of Development, 2012 61
Table 22: Trigeminal Neuralgia Therapeutics, Prominent Sponsors, 2012 63
List of Figures
Figure 1: Pain Distribution in the Various Nerve Branches in Trigeminal Neuralgia 7
Figure 2: Anatomy of Trigeminal Nerve 8
Figure 3: Pain Transmission in the Trigeminal System 9
Figure 4: Clinical Features of Trigeminal Neuralgia Pain 10
Figure 5: Progression of Trigeminal Neuralgia Over Time 11
Figure 6: Key Opinion Leader (KOL) Insights, Incidence of Trigeminal Neuralgia 13
Figure 7: Vascular Compression of Trigeminal Nerve in Trigeminal Neuralgia 15
Figure 8: Chronic Focal Demyelination of Neuron 16
Figure 9: Pathophysiology of Trigeminal Neuralgia 17
Figure 10: The IHS Diagnostic Criteria to Diagnose Classical and Symptomatic Trigeminal Neuralgia 19
Figure 11: KOL Insights, Diagnosis of Trigeminal Neuralgia 19
Figure 12: Differential Diagnosis of Trigeminal Neuralgia 21
Figure 13: KOL Insights, Guidelines for Management of Trigeminal Neuralgia 21
Figure 14: Treatment Algorithm for Trigeminal Neuralgia 22
Figure 15: KOL Insights, Treatment of Trigeminal Neuralgia 22
Figure 16: KOL Insights, Pharmacological Treatment for Trigeminal Neuralgia 23
Figure 17: Pharmacological Treatment for Trigeminal Neuralgia 25
Figure 18: Percutaneous Glycerol Injection Procedure 26
Figure 19: Percutaneous Balloon Compression Procedure 27
Figure 20: Percutaneous Radiofrequency Rhizotomy Procedure 28
Figure 21: Gamma Knife Stereotactic Radiosurgery 29
Figure 22: Microvascular Decompression for Trigeminal Neuralgia 30
Figure 23: Referral Pathway for Trigeminal Neuralgia 31
Figure 24: KOL Insights, Referral Pathway for Trigeminal Neuralgia 31
Figure 25: Trigeminal Neuralgia Therapeutics Market, Global, Revenue ($m), 2006-2011 33
Figure 26: Trigeminal Neuralgia Therapeutics Market, Global, Forecast ($m), 2011-2019 34
Figure 27: Trigeminal Neuralgia Therapeutics Market, The US, Revenue ($m), 2006-2011 35
Figure 28: Trigeminal Neuralgia Therapeutics Market, The US, Forecast ($m), 2011-2019 36
Figure 29: Trigeminal Neuralgia Therapeutics Market, France, Revenue ($m), 2006-2011 37
Figure 30: Trigeminal Neuralgia Therapeutics Market, France, Forecast ($m), 2011-2019 38
Figure 31: Trigeminal Neuralgia Therapeutics Market, Germany, Revenue ($m), 2006-2011 39
Figure 32: Trigeminal Neuralgia Therapeutics Market, Germany, Forecast ($m), 2011-2019 40
Figure 33: Trigeminal Neuralgia Therapeutics Market, Italy, Revenue ($m), 2006-2011 41
Figure 34: Trigeminal Neuralgia Therapeutics Market, Italy, Forecast ($m), 2011-2019 42
Figure 35: Trigeminal Neuralgia Therapeutics Market, Spain, Revenue ($m), 2006-2011 43
Figure 36: Trigeminal Neuralgia Therapeutics Market, Spain, Forecast ($m), 2011-2019 44
Figure 37: Trigeminal Neuralgia Therapeutics Market, The UK, Revenue ($m), 2006-2011 45
Figure 38: Trigeminal Neuralgia Therapeutics Market, The UK, Forecast ($m), 2011-2019 46
Figure 39: Trigeminal Neuralgia Therapeutics Market, Japan, Revenue ($m), 2006-2011 47
Figure 40: Trigeminal Neuralgia Therapeutics Market, Japan, Forecast ($m), 2011-2019 48
Figure 41: KOL Insights, Current Unmet Need for Trigeminal Neuralgia 51
Figure 42: Opportunity and Unmet Need in the Trigeminal Neuralgia Therapeutics Market, 2011 52
Figure 43: KOL Insights, Limitations of the Currently Available Treatment Options for Trigeminal Neuralgia 53
Figure 44: Trigeminal Neuralgia Therapeutics, Strategic Competitor Assessment, 2012 54
Figure 45: KOL Insights, Research for Future Treatment Options for Trigeminal Neuralgia 58
Figure 46: Trigeminal Neuralgia Therapeutics, Clinical Trials by Country, 2012 59
Figure 47: Trigeminal Neuralgia Therapeutics, Clinical Trials by Phase (%), 2012 60
Figure 48: Trigeminal Neuralgia Therapeutics, Clinical Trials by Status of Development (%), 2012 61
Figure 49: Trigeminal Neuralgia Therapeutics, Overall Sponsors (%), 2012 62
Figure 50: Trigeminal Neuralgia Therapeutics, Prominent Sponsors (%), 2012 62
Figure 51: Trigeminal Neuralgia Therapeutics Market, Drivers and Restraints, 2012 64
Figure 52: Implications for Future Market Competition in the Trigeminal Neuralgia Market, 2011 65
Figure 53: GlobalData Market Size Estimation 72
Figure 54: GlobalData Market Forecasting Model 73
Companies mentioned
Novartis
